| Document |
Document Title |
|
WO/2021/216642A1 |
The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2021/211741A1 |
Compounds having the structure of Formula (I) or pharmaceutically acceptable isomers, racemates, hydrates, solvates or salts thereof, where A, R1, R2a, R2b, R2c and R3 are as defined herein, are useful in the modulation of IL-12, IL-23 a...
|
|
WO/2021/210650A1 |
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, a...
|
|
WO/2021/210885A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting element comprising same.
|
|
WO/2021/209475A1 |
The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/211066A1 |
The present invention relates to a novel fluorene derivative having a structure of formula (I): wherein X is independently selected from a group consisting of Cl, Br, I, trifluoromethanesulfonate and 4-(trifluoromethyl)benzenesulfonate; ...
|
|
WO/2021/209383A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to meth...
|
|
WO/2021/207453A1 |
The present description relates to compounds of Formula (I), forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
|
|
WO/2021/204857A1 |
Compounds of the formula (I): Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2021/204188A1 |
A polycrystalline form of Utidelone, particularly relating to a semi-hydrated crystal form (A) of Utidelone, a preparation method therefor and a use of crystalline Utidelone in preparation of a pharmaceutical composition, especially the ...
|
|
WO/2021/204159A1 |
The present disclosure provides compounds represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, V, Q, T, n, p, q, r and s are as defined as set forth in the specification. The present disclosu...
|
|
WO/2021/207302A1 |
The present disclosure provides compounds of formula (I) and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
|
|
WO/2021/207186A1 |
One embodiment of the invention is a compound represented by Formula I: or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are CD38 inhibitors, which can be used to treat ...
|
|
WO/2021/207554A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/207511A1 |
Compounds according to formula (I), where R is as defined herein, have anti-cancer properties.
|
|
WO/2021/207172A1 |
Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that bin...
|
|
WO/2021/203811A1 |
The present invention relates to benzothiazinone compounds, a preparation method therefor and an application thereof as an anti-tuberculosis drug, and in particular to compounds having a benzothiazinone skeleton. The compounds are shown ...
|
|
WO/2021/203812A1 |
Disclosed are a benzothiazinone derivative, a preparation method therefor and use thereof as an anti-tuberculosis drug. The present invention specifically relates to a new class of compounds having a benzothiazinone skeleton. Such compou...
|
|
WO/2021/203673A1 |
The present application provides a nitrogen containing compound, an organic electroluminescent device using same, and an electronic device. A chemical structure of an organic compound in the present invention comprises a carbazole ring. ...
|
|
WO/2021/200934A1 |
The present invention provides a compound indicated by formula (I) or a salt thereof that is useful for the prevention or treatment of malaria (in the formula, each of the symbols is as defined in the specification).
|
|
WO/2021/201036A1 |
The present invention provides a target protein degradation inducing compound which is a bifunctional compound having, at one terminal, a portion that binds to VHL which is a substrate recognition protein of a ubiquitin ligase complex an...
|
|
WO/2021/198191A1 |
The present invention relates to a new class of quinazolinone derivatives of formula (I), and their uses for treating a cancer. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I).
|
|
WO/2021/203023A1 |
Indole derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD).
|
|
WO/2021/201576A1 |
The present invention relates to an anticancer agent for treating leukemia or solid cancers, comprising a novel benzothiazole derivative compound or a pharmaceutically acceptable salt thereof, wherein the benzothiazole derivative compoun...
|
|
WO/2021/203131A1 |
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
|
|
WO/2021/201577A1 |
The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are...
|
|
WO/2021/191384A1 |
Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treati...
|
|
WO/2021/192488A1 |
The purpose of the present invention is to provide a method for producing an amide bond-containing compound with which an active acid raw material having an aromatic heterocycle to which a carbonyl group is bonded can be easily removed. ...
|
|
WO/2021/195328A1 |
The present disclosure provides pharmaceutical formulations of treprostinil prodrugs and methods for their preparation and use in treating pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, and p...
|
|
WO/2021/195066A2 |
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-func...
|
|
WO/2021/193790A1 |
The present invention provides a compound which has a serotonin 5-HT2A receptor inverse agonist effect, a pharmaceutically acceptable salt thereof, and a composition which is for serotonin 5-HT2A receptor inverse agonism and which contai...
|
|
WO/2021/189143A1 |
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its...
|
|
WO/2021/187605A1 |
The present invention provides a compound useful as an active ingredient of a pharmaceutical composition for prophylaxis or treatment of premature ejaculation. Provided is a compound represented by formula (I) below [in the formula, A is...
|
|
WO/2021/188911A1 |
The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided co...
|
|
WO/2021/188431A1 |
The present disclosure provides methods for treating a malignant glioma comprising administering a therapeutically-effective amount of a TARP γ8 dependent AM PA receptor antagonist.
|
|
WO/2021/188944A1 |
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be u...
|
|
WO/2021/184339A1 |
Provided herein are the oxazolidinone compound of Formula (I) and pharmaceutically acceptable salts thereof. It also relates to compositions containing the compound of Formula (I). Provided herein also are methods for inhibiting growth o...
|
|
WO/2021/185312A1 |
Disclosed are a crystalline form of a Toll-like receptor 8 (TLR8) agonist as represented by formula (I) and a preparation method therefor. Further provided is an application of the crystalline form in the preparation of a drug for treati...
|
|
WO/2021/186185A1 |
The present disclosure relates to compounds of Formula (I) and to their utility in the treatment in a disease, disorder and/or condition associated with the peptide angiotensin II.
|
|
WO/2021/188537A1 |
Disclosed are bispecific compounds (degraders) that target cereblon (CRBN) for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds as research tools and to reduce advers...
|
|
WO/2021/186324A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharm...
|
|
WO/2021/182918A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein the pharmaceutical composition comprises an azole derivative or a pharmaceutically acceptable salt thereof. Specifically, the presen...
|
|
WO/2021/182280A1 |
Provided is a polymerizable liquid crystal composition which contains at least two types of polymerizable liquid crystal compound which have the same molecular weights but have different molecular structures and which are represented by ...
|
|
WO/2021/180966A1 |
The present invention relates to compounds, compositions and methods for treating cancers and disorders of cell proliferation and more particularly, methods of making and using compounds that modulate at least one of the proteins chosen ...
|
|
WO/2021/179394A1 |
A nucleic acid dye, a preparation method therefor and use thereof. The nucleic acid dye is a nucleic acid dye applicable to both agarose gel electrophoresis and polyacrylamide gel electrophoresis, and in particular, can be used for blue ...
|
|
WO/2021/182914A1 |
The present invention relates to a novel compound of chemical formula (I), a pharmaceutically acceptable salt, a hydrate and a solvate of the compound, and a hydrate or a solvate of the salt. The novel compound of the present invention e...
|
|
WO/2021/175913A1 |
Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments,...
|
|
WO/2021/178488A1 |
The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.
|
|
WO/2021/178339A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2021/175234A1 |
Disclosed are a benzothiazole compound represented by formula I and a medical use thereof, and specifically refers to a benzothiazole USP7 C-terminal domain regulating agent compound or a pharmaceutically acceptable salt, ester or solvat...
|
